Skip to main content
x

Roche slips further behind in perioperative lung cancer

Though Roche’s Tecentriq became the first ever anti-PD-(L)1 drug to be approved in perioperative lung cancer, the company has managed to lose this headstart. Merck & Co’s Keytruda trumped Tecentriq with an all-comers label in the adjuvant setting (Tecentriq’s label was limited to PD-L1 expressers), Bristol Myers Squibb’s Opdivo was first with a neoadjuvant approval, and now Opdivo threatens to add adjuvant use to its label, after the Checkmate-77T study was on Friday toplined positive for event-free survival. Keytruda presents a further threat, with success in the neoadjuvant Keynote-671 trial leading to a US filing on which the FDA is to decide by 16 October. And AstraZeneca’s Imfinzi has scored in the neoadjuvant Aegean trial, which featured at a plenary session of this year’s AACR. It is unclear whether Astra has filed these data with regulators, and Aegean is continuing to OS readout. Meanwhile, Roche’s Impower-030 trial, in a similar setting to Keynote-671 and Aegean, was initially due to yield data in 2021, but in February Roche said it was continuing to 2024, suggesting that interim analysis had failed to show a sufficiently positive effect; Impower-030’s clinicaltrials.gov entry now shows a primary completion date of January 2025. 

 

Key anti-PD-(L)1 MAb studies in perioperative NSCLC

 

Neoadjuvant NSCLC

Adjuvant NSCLC

Opdivo

Checkmate-816

Checkmate-77T**

 FDA approved in stage IB-IIIA all-comers, 4 Mar 2022;

Stage II-IIIB

EFS 31.6mth vs 20.8mth, pCR 24% vs 2.2%

Toplined positive for EFS, Sep 2023; continuing to OS assessment

Keytruda

Keynote-671*

Keynote-091 (Pearls)

Stage II, IIIA & resectable IIIB; filed, with 16 Oct 2023 Pdufa date

FDA approved in IB-IIIA all-comers, 27 Jan 2023

24mth EFS 62.4% vs 40.6%, pCR 18.1% vs 4.0%, 24mth OS 80.9% vs 77.6%

DFS 58.7mth vs 34.9mth in all-comers, but not significant in ≥50% PD-L1 expressers

Imfinzi

Aegean*

Mermaid-1

Stage IIA to "select" IIIB

Stage II-III; 2024 readout

EFS HR=0.68, pCR 17.2% vs 4.3%; continuing to OS assessment

Tecentriq

Impower-030*

Impower-010

Stage II, IIIA & "select IIIB"; readout delayed from 2021 to 2022 to 2024 to 2025

FDA approved in PD-L1 +ve (≥1%) stage II-IIIA disease, 15 Oct 2021

DFS NR vs 35.3mth in PD-L1 expressers

Notes: *also has an adjuvant stage; **also has a neoadjuvant stage. EFS=event-free survival; pCR=pathological complete response; DFS=disease-free survival. Source: OncologyPipeline & company expectations of timing.

Tags

Molecular Drug Targets